Fig. 8

Inhibition of SPP1 alleviates myocardial injury in VMC mice: (A) Timeline of SPP1 inhibition treatment. (B) Weight changes of the control, CVB3 and SEI + CVB3 mice in the following 7 days after treatment. (C) Western blotting analysis of SPP1 in cardiac tissues from control, CVB3 and SEI + CVB3 mice. (D) The expression levels of SPP1 in plasma from control, CVB3 and SEI + CVB3 mice. (E) Relative Ccl2 and Ccl7 mRNA levels of cardiac tissues from control, CVB3 and SEI + CVB3 mice. (F) Representative immunofluorescent staining of macrophages (CD68, green), nuclei (DAPI, blue) and SPP1 (red) in cardiac tissues from control, CVB3 and SEI + CVB3 mice. Scale bars: 125 μm. (G) Representative parasternal long axis 2-dimensional and M-mode echocardiography images from control, CVB3 and SEI + CVB3 mice. (H) Cardiac immune infiltration status in different groups. Scale bars: 50 μm. (I) EF and FS of control, CVB3 and SEI + CVB3 mice. (J) Myocarditis scores for cardiac immune infiltration from control, CVB3 and SEI + CVB3 mice. (K) Representative TUNEL staining of heart sections from control, CVB3 and SEI + CVB3 mice. (L) Relative mRNA levels of inflammatory factors (IL-1β, IL-6, TNF-α) in cardiac tissues from control, CVB3 and SEI + CVB3 mice. (M)The levels of cTnT in mouse plasma. (N) Relative Spp1 mRNA levels of cardiac tissues from control, CVB3 and SEI + CVB3 mice. (O) The levels of SPP1 in plasma from control and myocarditis children. ANOVA was used for analysis. Data are presented as mean ± SD (n ≥ 5 biologically independent samples). ***P < 0.001, **P < 0.01, *P < 0.05, ns P > 0.05